- Dec 11, 2023
- 9 min
top of page
About
ResolutionRx Ltd (Australian Company Number a/k/a ACN 664 925 651) was formed in Australia on 11th January 2023 by RespireRx as an unlisted public company for the purpose of discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including sleep related breathing disorders such as obstructive sleep apnoea (“OSA”).
Automated Slide Deck
Automated Slide Deck
Repurposing Dronabinol for OSA
About Dronabinol
Dronabinol was first approved in the United States in 1985 and is currently approved for anorexia associated with AIDS and chemotherapy induced nausea and vomiting. We're developing dronabinol for OSA.
Obstructive Sleep Apnoea
Obstructive Sleep Apnoea (OSA) is associated with decreased quality of life, and significant functional impairment. According to an August 2019 publication in Lancet Respiratory Medicine, afflicts more than 90 million people in the United States, Australia, Germany and the United Kingdom.
Clinical Trials
ResolutionRx has obtained the rights from RespireRx, to develop and commercialize cannabinoids such as dronabinol for sleep related and other breathing disorders.
bottom of page